Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AdAlta Ltd. ( (AU:1AD) ) just unveiled an announcement.
AdAlta Limited has completed a cash repayment of $405,132 to New Life Sciences Capital (NLSC), settling the remaining balance of their investment agreement without issuing additional shares. This strategic move, facilitated by NLSC’s initial investment, has supported AdAlta’s development of its cellular immunotherapy strategy, positioning the company to advance its CAR-T asset negotiations and raise private capital for global cancer patient treatments.
More about AdAlta Ltd.
AdAlta Limited is a clinical stage biotechnology company focused on developing effective cellular immunotherapies for treating solid cancers. The company employs an ‘East to West’ strategy, integrating Asian T cell therapy innovations with Australia’s clinical and manufacturing expertise to bridge Eastern innovations with Western markets. AdAlta is committed to addressing the underserved solid tumor segment, which constitutes 90% of cancers, and aims to lead in this high-growth market projected to reach US$20.3 billion by 2028. The company also offers AD-214, a fusion protein for fibrotic diseases, available for partnering after successful Phase I trials.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$8.45M
Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.